May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Vascular Endothelial Growth Factor in Untreated Fellow Eyes of Eyes Injected With Intravitreal Bevacizumab
Author Affiliations & Notes
  • O. Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • H. Kawamura
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Kakinoki
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • T. Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Ohji
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Footnotes
    Commercial Relationships  O. Sawada, None; H. Kawamura, None; M. Kakinoki, None; T. Sawada, None; M. Ohji, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5588. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Sawada, H. Kawamura, M. Kakinoki, T. Sawada, M. Ohji; Vascular Endothelial Growth Factor in Untreated Fellow Eyes of Eyes Injected With Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5588. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the effect on untreated fellow eyes of eyes treated with an intravitreal injection of bevacizumab.

Methods: : Bevacizumab (1.25 mg/0.05 ml) was injected into the vitreous cavity of one eye (the first eye) as a preoperative adjunctive therapy for proliferative diabetic retinopathy; vitrectomy was performed 1 week later. Immediately after vitrectomy, bevacizumab (1.25 mg/0.05 ml) was injected into the fellow eye (the second eye) followed by vitrectomy 1 week later. Aqueous humor samples were obtained from both eyes in four cases just before intravitreal injection of bevacizumab and just before vitrectomy 1 week later. Vascular endothelial growth factor (VEGF) concentrations in the aqueous humor were measured by enzyme-linked immunosorbent assay (ELISA).

Results: : VEGF concentrations in the aqueous humor of the first eyes ranged from 146 to 392 pg/ml (mean, 278±98) before intravitreal injection of bevacizumab, 1 week later, VEGF concentrations of the injected eyes were less than 31 pg/ml, the lower limit of the ELISA, in all cases (p < 0.001).The concentrations in the uninjected fellow eyes ranged 181 to 551 pg/mL (mean, 384±133 pg/mL) .

Conclusions: : There seemed to be no or a minimal effect of the intravitreal injections of bevacizumab on the uninjected fellow eyes.

Keywords: diabetic retinopathy • vascular endothelial growth factor • aqueous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×